Ruxolitinib Cream Improves Repigmentation, QOL in Vitiligo, but Better Patient Education, Guidance Are Needed

This content was developed independently and is not endorsed by the American Academy of Dermatology.

Ruxolitinib cream (Opzelura; Incyte) promotes facial repigmentation and improves quality of life (QOL) in patients with vitiligo, though real-world data highlight care gaps and the need for better patient education and guidance, according to abstracts presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado.^1,2

Approvals and Clinical Trial Advancements

Ruxolitinib cream, a topical Janus kinase 1/2 inhibitor, was initially approved by the FDA in September 2021 for the treatment of atopic dermatitis.³ The approval was based on data from the TRuE-AD clinical trial program, consisting of the phase 3 studies TRuE-AD1 (NCT03745638) and TRuE-AD2 (NCT03745651).

Less than a year later, in July 2022, ruxolitinib cream 1.5% received accelerated approval for the treatment of vitiligo in patients 12 years and older, becoming the first therapy approved for repigmentation in this population.⁴ The decision was supported by data from the TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) studies.

Greater Facial Repigmentation With Ruxolitinib Cream Linked to Improved QOL

Vitiligo causes skin depigmentation and is associated with a significant QOL burden.¹ Because of this, investigators of the first poster, “Association Between Repigmentation and Quality of Life Among Patients With Vitiligo Treated With Ruxolitinib Cream in the TRuE-V Studies,” conducted a post hoc analysis of patients who applied ruxolitinib cream 1.5% twice daily throughout the TRuE-V trials to assess the association between clinically meaningful repigmentation thresholds and QOL improvements.

In the primary analysis of these studies, a significantly greater proportion of patients receiving ruxolitinib cream 1.5% twice daily (BID) achieved at least a 75% improvement from baseline in the facial Vitiligo Area Scoring Index (F-VASI75) and at least a 50% improvement in total body VASI vs those receiving vehicle BID at week 24.⁴

Building on these findings, the investigators categorized patients based on whether they achieved at least 50%, 75%, or 90% improvement from baseline in F-VASI (F-VASI50/75/90) at weeks 24, 52, and 104.¹ They also assessed mean change from baseline (CFB) in Dermatology Life Quality Index (DLQI) and Vitiligo-Specific QoL Instrument (VitiQoL) scores.

At week 24, patients achieving F-VASI75 and F-VASI90 demonstrated significantly greater QOL improvements than nonresponders for both DLQI (F-VASI75: mean CFB, –1.8 [n = 109] vs 0.9 [n = 251]; F-VASI90: mean CFB, –2.4 [n = 55] vs –1.0 [n = 305]; both P < .05) and VitiQoL (F-VASI75: mean CFB, –8.9 [n = 121] vs –5.0 [n = 272]; P < .05; F-VASI90: mean CFB, –12.1 [n = 64] vs –5.1 [n = 329]; P < .01). The researchers noted that those achieving F-VASI50 also experienced QOL improvements, though to a lesser degree (P > .05).

A similar pattern was observed at week 52, with greater improvements in DLQI and VitiQoL among all responders vs nonresponders. However, by week 104, QOL improvements were most pronounced among patients achieving F-VASI50, whereas differences between F-VASI75/90 responders and nonresponders were less pronounced.

The researchers noted that this may reflect gradual repigmentation among nonresponders over long-term treatment without reaching F-VASI75/90 thresholds. It may also indicate patients' psychosocial acclimation to treatment over time or the impact of smaller subgroup sizes at week 104.

Overall, the researchers expressed confidence in their findings.

“Among patients with vitiligo treated with ruxolitinib cream, repigmentation was associated with meaningful QoL improvements,” the authors concluded. “Higher facial repigmentation thresholds (ie, F-VASI75/90 response) were associated with significantly greater QOL improvements.”

Real-World Use Highlights Gaps in Vitiligo Care, Treatment Awareness

Building on the first poster’s findings showing QOL improvements among these patients, investigators of the second poster, “Real-World Factors Influencing Vitiligo Care: Insights From a Patient Survey Assessing the Use of Ruxolitinib Cream,” noted that there is currently a lack of real-world data regarding ruxolitinib cream treatment patterns among patients with vitiligo and the factors influencing its use.²

To address this knowledge gap, they conducted a retrospective, cross-sectional online survey between January 22 and February 17, 2025, through the MyVitiligoTeam platform, a social network and online support group for people with vitiligo. Eligible participants were US adults 21 years or older with vitiligo, and the survey included 43 questions, taking about 12 to 15 minutes to complete.

The survey had 309 respondents, most of whom were female and younger than 65. The researchers underscored that these real-world ruxolitinib cream users were more racially and ethnically diverse than those included in the TRuE-V1/V2 studies, which included a higher proportion of White patients.

Among respondents, 20.1% were currently using ruxolitinib cream, whereas 11.3% were previous users. However, 68.6% were naive users, as they had never used ruxolitinib cream, highlighting the ongoing need for continued education regarding the availability of this therapy.

Current users more commonly reported being treated by dermatologists than previous or naive users. Conversely, more than 25% of previous users and over 50% of naive users reported not seeing any health care professional for their vitiligo. As a result, about 75% of previous and naive users reported not receiving any treatment at the time of the survey.

Regarding treatment patterns, the survey responses indicated that most current users applied ruxolitinib cream twice daily (74.2%) rather than once daily (22.6%), typically to 10% or less of their body surface area (91.9%). In addition, 82.3% of current users reported they intended to continue the treatment.

The findings also indicated that discussions between patients and health care professionals regarding the importance of treatment persistence are connected with a longer duration of ruxolitinib cream treatment. As a result, a lack of discussions surrounding long-term treatment persistence likely contributes to early discontinuation, as 48.6% of previous users reported discontinuing ruxolitinib cream due to a perceived lack of efficacy.

Despite this, 42.9% of previous users indicated they would consider restarting the treatment if they received better guidance, including information regarding repigmentation expectations and the understanding of lessening adverse effects.

"People starting a new treatment often hope for immediate results, and they can understandably get discouraged before the treatment has a chance to work,” Beth Schneider, senior research director at MyHealthTeam and one of the study’s authors, said in a statement to The American Journal of Managed Care^®. “The recent vitiligo research conducted in partnership with Incyte highlights the important role dermatologists play in setting expectations and encouraging patience when using ruxolitinib to treat vitiligo.”

References

1. Gooderham M, Bose RH, Devani AR, et al. Association between repigmentation and quality of life among patients with vitiligo treated with ruxolitinib cream in the TRuE-V studies. Presented at: 2026 AAD Annual Meeting; March 27-31, 2026; Denver, CO. 75247.
2. Ambati S, Sturm D, O’Brien C, Schneider B. Real-world factors influencing vitiligo care: insights from a patient survey assessing the use of ruxolitinib cream. Presented at: 2026 AAD Annual Meeting; March 27-31, 2026; Denver, CO. Poster 75258.
3. AJMC Staff. Ruxolitinib cream approved for short-term treatment of atopic dermatitis. AJMC^®. September 22, 2021. Accessed March 27, 2026. https://www.ajmc.com/view/ruxolitinib-cream-approved-for-short-term-treatment-of-atopic-dermatitis
4. Gavidia M. FDA approves ruxolitinib cream as first repigmentation therapy for vitiligo. AJMC. July 19, 2022. Accessed March 27, 2026. https://www.ajmc.com/view/fda-approves-ruxolitinib-cream-as-first-repigmentation-therapy-for-vitiligo